The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and ...

Roche announced that it has struck an exclusive deal with Denmark's Zealand Pharma to develop and market petrelintide, a new treatment for obesity.

Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...

Pharmaceutical giant Roche announces opening of an innovation centre at Harvard University's corporate research campus.

Roche, announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will further strengthen the long-standing partnership in areas such ...

The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to drive innovation in d ...

Swiss companies. Large corporates are not dependent on the domestic market. However, it could become more important for ...

Today, Roche is headquartered in Basel, Switzerland. The company now employs 80,000 people across a number of pharmaceutical and diagnostic sites across the world. The first of many successes ...

and is expected to impact over 4 billion people globally by 2035 Basel, 12 March 2025 - Roche (SIX: RO, ROG; The new center will be a hub for both Roche and Genentech, bringing together expertise ...

before transferring to Roche's Basel headquarters in Switzerland to take up her current role in 2019. A graduate of The George Washington University with a BBA in Business, Economics, and Public ...

Roche announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston, establishing a h ...